EQS-News: Marinomed Biotech AG / Key word(s): Personnel
Marinomed Biotech AG: Lucia Ziegler new Head of Investor & Public
Relations
01.03.2024 / 07:45 CET/CEST
The issuer is solely responsible for the content of this announcement.
══════════════════════════════════════════════════════════════════════════
Marinomed Biotech AG: Lucia Ziegler new Head of Investor & Public
Relations
Korneuburg, Austria, 1 March 2024 – Lucia Ziegler will take over the newly
integrated “Investor & Public Relations” department at Marinomed Biotech
AG (VSE:MARI) as of the beginning of March 2024. In addition to her
previous PR tasks, Lucia Ziegler will also be responsible for the biotech
company’s IR activities. She takes over the IR agendas from Stephanie
Kniep, who will remain connected with Marinomed.
Lucia Ziegler holds a Master of Science in Molecular Biology from the
University of Vienna and has successfully built up the Public Relations
and Social Media activities at Marinomed over the past three years. “With
IR and PR activities under one management, we are bringing together what
belongs together. We are paving the way for even better and more efficient
stakeholder communications. Lucia Ziegler has already set important
accents in the perception of Marinomed with the redesign of the website
and further development of the annual report. In her extended area of
responsibility, she will continue to sharpen the presentation of
Marinomed’s positioning, strategy and future potential to shareholders,
investors, business partners and the media in a synchronized manner. I
would like to thank Stephanie Kniep for her dedication and the valuable
contribution she has made to building up our IR activities on the
international capital markets,” Andreas Grassauer, CEO of Marinomed,
comments.
About Marinomed Biotech AG
Marinomed Biotech AG is an Austrian, science-based biotech company with a
growing development pipeline and globally marketed therapeutics. The
Company develops innovative patent-protected products in the therapeutic
areas immunology and virology based on the platform Marinosolv® and the
virus-blocking activity of Carragelose®. The Marinosolv® technology
improves the solubility and bioavailability of hardly soluble compounds
and is used to develop new therapeutics for autoreactive immune disorders.
The virology segment includes Carragelose®-based over-the-counter (OTC)
products to prevent and treat respiratory viral infections that are
partnered in more than 40 countries. The Company is headquartered in
Korneuburg, Austria, and is listed on the prime market of the Vienna Stock
Exchange (VSE:MARI). For further information, please visit:
(1) https://www.marinomed.com.
For further inquiries contact:
Marinomed Biotech AG International Media Contact
IR & PR: Lucia Ziegler Metrum Communications: Roland Mayrl
T: +43 2262 90300 158 T: +43 664 6126228
E-Mail: (2)ir@marinomed.com E-Mail: (4)marinomed@metrum.at E-Mail: (3)pr@marinomed.com
══════════════════════════════════════════════════════════════════════════
01.03.2024 CET/CEST This Corporate News was distributed by EQS Group AG.
www.eqs.com
══════════════════════════════════════════════════════════════════════════
Language: English
Company: Marinomed Biotech AG
Hovengasse 25
2100 Korneuburg
Austria
Phone: +43 2262 90300
E-mail: office@marinomed.com
Internet: www.marinomed.com
ISIN: ATMARINOMED6
WKN: A2N9MM
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt,
Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange
(Official Market)
EQS News ID: 1848777
End of News EQS News Service
1848777 01.03.2024 CET/CEST
References
Visible links
1. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=b364e041c58da1aeff9758a10a9b0152&application_id=1848777&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
2. and@marinomed.com
3. pr@marinomed.com
4. marinomed@metrum.at